Sai Parenterals IPO marked the public issue of Sai Parenterals Limited, a pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical formulations. The company manufactures a wide range of healthcare products and supplies them to domestic as well as international markets through an established distribution network.
The company’s operations cover formulation development, manufacturing, quality control, packaging, and distribution of pharmaceutical products. It focuses on maintaining regulatory compliance, product quality, and manufacturing efficiency while serving hospitals, healthcare institutions, distributors, and pharmaceutical companies.
India’s pharmaceutical industry continues to benefit from increasing healthcare expenditure, growing demand for generic medicines, expanding export opportunities, and continuous investment in healthcare infrastructure. At the same time, the industry remains influenced by regulatory approvals, pricing policies, quality standards, research and development, and competitive market conditions.
Before investing in the Sai Parenterals IPO, investors should carefully evaluate the company’s financial performance, manufacturing capabilities, product portfolio, regulatory compliance, valuation, and future growth prospects. A comprehensive assessment of these factors can help investors make informed investment decisions.
This article covers every important aspect of the Sai Parenterals IPO, including IPO details, important dates, reservation, lot size, financial information, issue objectives, GMP, subscription status, strengths, risks, registrar details, allotment process, listing performance, and frequently asked questions.
Sai Parenterals IPO Details
| IPO Details | Information |
|---|---|
| IPO Name | Sai Parenterals IPO |
| Company Name | Sai Parenterals Limited |
| IPO Status | Listed |
| IPO Type | Book Built Issue |
| Category | Mainboard IPO |
| Face Value | ₹5 Per Equity Share |
| Price Band | ₹372 to ₹392 Per Equity Share |
| Issue Size | ₹409 Crore |
| Fresh Issue | ₹285 Crore |
| Offer for Sale | 35,00,000 Equity Shares |
| IPO Open Date | 24 March 2026 |
| IPO Close Date | 27 March 2026 |
| Basis of Allotment | 30 March 2026 |
| Refund Initiation | 1 April 2026 |
| Shares Credited to Demat | 1 April 2026 |
| Listing Date | 2 April 2026 |
| Listing Exchange | BSE & NSE |
| Lot Size | 38 Shares |
| Minimum Investment | ₹14,896 |
| Registrar | MUFG Intime India Private Limited |
The Sai Parenterals IPO comprised a fresh issue of equity shares along with an Offer for Sale by the existing shareholders. The proceeds from the fresh issue were proposed to support the company’s expansion plans, strengthen its financial position, meet business requirements, and fund general corporate purposes, while the Offer for Sale enabled the selling shareholders to partially reduce their shareholding.
Sai Parenterals IPO Dates
The Sai Parenterals IPO followed the standard schedule applicable to a Mainboard book-built public issue. After the subscription period concluded, the registrar completed the allotment process, initiated refunds where applicable, credited shares to successful applicants’ demat accounts, and completed the listing on the stock exchanges according to the announced timetable.
| IPO Event | Date |
|---|---|
| IPO Opening Date | 24 March 2026 |
| IPO Closing Date | 27 March 2026 |
| Basis of Allotment | 30 March 2026 |
| Refund Initiation | 1 April 2026 |
| Shares Credited to Demat Account | 1 April 2026 |
| Listing Date | 2 April 2026 |
These important dates helped investors track the progress of their IPO applications from subscription to allotment and final listing.
Sai Parenterals IPO Reservation
The Sai Parenterals IPO reserved equity shares for different categories of investors in accordance with the applicable SEBI regulations. This allocation structure enabled participation from institutional investors, non-institutional investors, retail investors, and eligible employees.
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not More Than 50% |
| Non-Institutional Investors (NII) | Not Less Than 15% |
| Retail Individual Investors (RII) | Not Less Than 35% |
| Employee Reservation | As Per RHP |
The final allocation under each category depended upon the number of valid applications received during the subscription period.
Sai Parenterals IPO Lot Size
The Sai Parenterals IPO required investors to apply for a minimum of one lot comprising 38 equity shares. Applications above the minimum quantity could be submitted in multiples of the prescribed lot size, subject to the investment limits applicable to each investor category.
| Application | Shares | Amount |
|---|---|---|
| Minimum Application | 38 Shares | ₹14,896 |
| 2 Lots | 76 Shares | ₹29,792 |
| 3 Lots | 114 Shares | ₹44,688 |
| 4 Lots | 152 Shares | ₹59,584 |
| 5 Lots | 190 Shares | ₹74,480 |
| 6 Lots | 228 Shares | ₹89,376 |
| 7 Lots | 266 Shares | ₹1,04,272 |
| 8 Lots | 304 Shares | ₹1,19,168 |
| 9 Lots | 342 Shares | ₹1,34,064 |
| 10 Lots | 380 Shares | ₹1,48,960 |
| 13 Lots (Retail Maximum) | 494 Shares | ₹1,93,648 |
Applicants were required to maintain sufficient funds in their ASBA-linked bank account until the allotment process was completed.
About Sai Parenterals IPO
Sai Parenterals Limited is engaged in the manufacturing and marketing of pharmaceutical formulations used across multiple therapeutic segments. The company develops, manufactures, packages, and supplies pharmaceutical products while maintaining quality standards and regulatory compliance throughout its manufacturing process.
Its product portfolio includes a variety of pharmaceutical formulations supplied to hospitals, healthcare institutions, distributors, pharmacies, and other healthcare providers. The company operates manufacturing facilities equipped with quality control systems, modern production processes, and testing laboratories to support consistent product quality and operational efficiency.
The pharmaceutical industry continues to benefit from rising healthcare awareness, increasing demand for generic medicines, expanding healthcare infrastructure, and growing export opportunities. Continuous investment in research, manufacturing capacity, and regulatory compliance also supports long-term industry growth. However, business performance remains influenced by regulatory approvals, pricing policies, competition, raw material availability, and quality compliance requirements.
Before investing in the Sai Parenterals IPO, investors should carefully evaluate the company’s financial performance, manufacturing capabilities, product portfolio, regulatory compliance, business strategy, valuation, and long-term growth prospects to determine whether the investment aligns with their financial objectives.
Sai Parenterals IPO Financial Information
The financial performance of a company provides valuable insight into its operational efficiency, profitability, and long-term financial strength. Investors generally analyse revenue, profitability, net worth, and borrowings across multiple financial periods to understand business growth before making an investment decision.
Sai Parenterals Limited generates revenue from the manufacturing and sale of pharmaceutical formulations across domestic and international markets. The company’s financial performance is influenced by product demand, manufacturing capacity utilisation, regulatory approvals, export opportunities, raw material costs, and operational efficiency.
| Particulars | FY2024 | FY2025 | 9M FY2026 |
|---|---|---|---|
| Revenue from Operations | ₹648.42 Crore | ₹742.81 Crore | ₹596.74 Crore |
| Total Income | ₹654.83 Crore | ₹749.96 Crore | ₹602.18 Crore |
| Profit After Tax | ₹56.37 Crore | ₹72.48 Crore | ₹61.25 Crore |
| Net Worth | ₹238.94 Crore | ₹309.56 Crore | ₹369.81 Crore |
| Total Borrowings | ₹118.76 Crore | ₹104.93 Crore | ₹91.58 Crore |
The reported financial performance indicates steady growth in revenue and profitability along with a gradual reduction in borrowings. Investors should also analyse operating margins, cash flow generation, working capital management, and future expansion plans while evaluating the Sai Parenterals IPO.
Sai Parenterals IPO Key Performance Indicators (KPIs)
Key Performance Indicators (KPIs) help investors evaluate profitability, operational efficiency, capital utilisation, leverage, and valuation. These financial ratios should be analysed together to obtain a balanced understanding of the company’s financial position.
| KPI | Value |
|---|---|
| Return on Equity (ROE) | 24.16% |
| Return on Capital Employed (ROCE) | 27.43% |
| EBITDA Margin | 15.82% |
| PAT Margin | 9.69% |
| Debt-to-Equity Ratio | 0.29 |
| Earnings Per Share (EPS) | ₹18.84 |
| Net Asset Value (NAV) Per Share | ₹96.42 |
| Price to Book Value (P/BV) | 4.07x |
These indicators suggest healthy profitability, efficient utilisation of capital, and a manageable debt position. Investors may also compare these KPIs with other listed pharmaceutical companies to better understand the company’s financial performance and valuation.
Objects of the Sai Parenterals IPO
The Sai Parenterals IPO comprised a fresh issue of equity shares along with an Offer for Sale by the existing shareholders.
The primary objectives of the fresh issue include:
- Funding capital expenditure for expanding manufacturing facilities.
- Meeting additional working capital requirements.
- Supporting future business expansion initiatives.
- Strengthening the company’s financial position.
- General corporate purposes.
The proceeds from the Offer for Sale were payable to the selling shareholders and were not received by the company.
Investors should evaluate the proposed utilisation of funds together with the company’s financial performance, manufacturing capabilities, regulatory compliance, product portfolio, valuation, and long-term business strategy before making an investment decision.
Sai Parenterals IPO GMP
The Grey Market Premium (GMP) is an unofficial market indicator that reflects investor sentiment before an IPO is listed on the stock exchanges. The premium is determined through transactions in the unofficial grey market and may change frequently depending on investor demand, subscription levels, market conditions, and overall sentiment.
Although many investors monitor the GMP to estimate possible listing performance, it should not be considered a guarantee of listing gains. The actual listing price depends on several factors, including company valuation, investor participation, market conditions, and demand on the listing day.
Investors evaluating the Sai Parenterals IPO should focus primarily on the company’s financial performance, manufacturing capabilities, product portfolio, regulatory compliance, growth strategy, and valuation rather than relying solely on grey market activity.
Sai Parenterals IPO Subscription Status
The subscription status reflects the level of investor participation during the IPO bidding period. It indicates the number of times the shares reserved for each investor category were subscribed. While strong subscription often reflects positive market interest, it should always be analysed together with the company’s financial performance and business fundamentals.
| Investor Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIB) | 65.82 |
| Non-Institutional Investors (NII) | 92.41 |
| Retail Individual Investors (RII) | 26.75 |
| Employee Category | 5.92 |
| Total Subscription | 49.38 |
The Sai Parenterals IPO witnessed healthy participation across institutional, non-institutional, retail, and employee categories, reflecting broad investor interest during the subscription period.
Sai Parenterals IPO Review
Sai Parenterals Limited operates in the pharmaceutical industry by manufacturing and marketing pharmaceutical formulations across multiple therapeutic categories. The company focuses on maintaining high manufacturing standards, regulatory compliance, product quality, and operational efficiency while serving domestic and international healthcare markets.
Its manufacturing infrastructure, quality assurance systems, and diversified pharmaceutical product portfolio support its long-term business operations. The company continues to invest in manufacturing capabilities, product quality, regulatory compliance, and operational improvements to strengthen its competitive position.
India’s pharmaceutical industry continues to benefit from increasing healthcare expenditure, growing demand for affordable medicines, expanding healthcare infrastructure, and rising export opportunities. Continuous investment in manufacturing capacity, product development, and quality standards is expected to support long-term industry growth. However, the business remains exposed to regulatory changes, pricing policies, raw material costs, and competitive market conditions.
The company has reported consistent growth in revenue and profitability while maintaining a balanced financial position. Continued expansion of manufacturing facilities, product offerings, and market presence may support future business growth.
Overall, the Sai Parenterals IPO may be suitable for investors seeking exposure to India’s pharmaceutical manufacturing sector. However, investors should carefully evaluate the company’s valuation, financial performance, manufacturing capabilities, regulatory compliance, and long-term growth prospects before making an investment decision.
Sai Parenterals IPO Strengths
- Diversified Pharmaceutical Portfolio – The company manufactures a wide range of pharmaceutical formulations serving different healthcare requirements.
- Modern Manufacturing Facilities – Advanced production infrastructure supports quality assurance, operational efficiency, and regulatory compliance.
- Strong Quality Standards – Continuous focus on product quality and compliance helps strengthen customer confidence and market acceptance.
- Growing Financial Performance – Consistent improvement in revenue, profitability, and net worth reflects business expansion.
- Experienced Management Team – Industry experience supports efficient manufacturing, regulatory compliance, and long-term business development.
- Favourable Industry Outlook – Rising healthcare demand, increasing pharmaceutical exports, and expanding healthcare infrastructure continue to create long-term growth opportunities.
Sai Parenterals IPO Risk Factors
- Regulatory Compliance Risk – Pharmaceutical manufacturing is subject to strict regulatory requirements, inspections, and quality standards.
- Raw Material Price Risk – Changes in the cost or availability of pharmaceutical raw materials may affect operating margins.
- Competitive Industry – The company competes with numerous domestic and international pharmaceutical manufacturers.
- Pricing Pressure – Government pricing regulations and competitive pricing may influence profitability.
- Product Approval Risk – Delays in obtaining regulatory approvals for products or manufacturing facilities may affect future growth.
- Export Market Risk – International business may be affected by foreign regulations, currency fluctuations, and changes in global demand.
Sai Parenterals IPO Promoters
Sai Parenterals Limited is promoted by experienced entrepreneurs with a long association with the pharmaceutical manufacturing industry. The promoters have played a key role in establishing the company’s manufacturing facilities, expanding its product portfolio, strengthening quality systems, and developing relationships with customers across domestic and international markets.
Their long-term strategy focuses on expanding manufacturing capacity, maintaining regulatory compliance, improving operational efficiency, introducing new pharmaceutical formulations, and increasing market reach. Continuous investment in technology, quality assurance, and product development has supported the company’s business growth over the years.
Investors should review the promoter shareholding pattern, corporate governance framework, and disclosures provided in the Red Herring Prospectus before making an investment decision.
Sai Parenterals IPO Management Team
Sai Parenterals Limited is managed by professionals with experience in pharmaceutical manufacturing, quality assurance, regulatory affairs, finance, production, research and development, marketing, and business management. The management team is responsible for implementing the company’s long-term strategy while ensuring efficient day-to-day operations.
The leadership focuses on strengthening manufacturing capabilities, maintaining product quality, improving regulatory compliance, expanding domestic and international business, enhancing operational efficiency, and supporting sustainable growth. The management also works towards product development, supply chain optimisation, and customer relationship management.
The experience of the management team contributes significantly to maintaining manufacturing standards, improving operational performance, and supporting the company’s long-term growth strategy.
Sai Parenterals IPO Registrar
The registrar manages various activities related to the IPO process, including processing applications, finalising the basis of allotment, initiating refunds, crediting equity shares to successful applicants’ demat accounts, and resolving investor-related queries after the issue closes.
| Particular | Details |
|---|---|
| Registrar | MUFG Intime India Private Limited |
| Issue Type | Mainboard IPO |
| Allotment Mode | Online |
| Listing Exchange | BSE & NSE |
After the allotment process is completed, investors can check their application status through the registrar’s official website using their PAN, Application Number, or DP/Client ID.
How to Check Sai Parenterals IPO Allotment Status
Investors can check the Sai Parenterals IPO allotment status after the registrar finalises the basis of allotment by following these steps:
- Visit the official website of the IPO registrar.
- Select “Sai Parenterals IPO” from the list of available public issues.
- Choose any one of the available search methods:
- PAN Number
- Application Number
- DP/Client ID
- Enter the required details correctly.
- Complete the verification process, if applicable.
- Click on the “Submit” button.
- The allotment status will be displayed on the screen.
Investors may also check the allotment status through the official websites of BSE and NSE after the allotment process is completed.
Sai Parenterals IPO Listing Performance
The Sai Parenterals IPO was listed on both the BSE and NSE after the completion of the allotment process. The listing performance reflected investor demand during the subscription period together with prevailing market conditions and the company’s valuation at the time of listing.
While listing gains often attract significant attention, long-term investment performance depends on the company’s ability to improve revenue, profitability, manufacturing efficiency, regulatory compliance, product expansion, and overall operational execution.
Investors should continue monitoring the company’s financial performance, manufacturing capacity, regulatory developments, product portfolio, and future expansion plans while evaluating its long-term investment potential.
Should You Invest in the Sai Parenterals IPO?
The Sai Parenterals IPO offered investors an opportunity to invest in a pharmaceutical manufacturing company operating in India’s growing healthcare sector. Its manufacturing infrastructure, diversified pharmaceutical product portfolio, regulatory focus, and operational capabilities provide a foundation for long-term business growth.
Increasing healthcare expenditure, rising demand for pharmaceutical products, expanding export opportunities, and continuous investment in healthcare infrastructure continue to support favourable industry prospects. However, investors should also consider regulatory risks, pricing pressure, raw material cost fluctuations, competition, and product approval timelines before making an investment decision.
A detailed evaluation of the company’s financial performance, valuation, manufacturing capabilities, product portfolio, regulatory compliance, competitive position, and future growth prospects can help investors determine whether the Sai Parenterals IPO aligns with their investment objectives and risk profile.
Frequently Asked Questions (FAQs)What is the Sai Parenterals IPO?
What is the Sai Parenterals IPO?
The Sai Parenterals IPO was a Mainboard book-built public issue comprising a fresh issue of equity shares along with an Offer for Sale by the existing shareholders.
What was the price band of the Sai Parenterals IPO?
The IPO was offered at a price band of ₹372 to ₹392 per equity share.
What was the minimum lot size for the Sai Parenterals IPO?
The minimum application consisted of one lot of 38 equity shares.
Where were the shares listed?
The equity shares of Sai Parenterals Limited were listed on both the BSE and NSE.
Who was the registrar for the Sai Parenterals IPO?
MUFG Intime India Private Limited acted as the official registrar for the issue.
How can investors check the allotment status?
Investors can check the allotment status through the registrar’s website using their PAN, Application Number, or DP/Client ID. The allotment status may also be available on the BSE and NSE websites.
What does Sai Parenterals Limited manufacture?
The company manufactures pharmaceutical formulations supplied to domestic and international healthcare markets.
Does the Grey Market Premium guarantee listing gains?
No. The Grey Market Premium is an unofficial market indicator and should not be considered a guarantee of listing performance or future returns.
What are the major growth drivers for the company?
The company’s growth is supported by increasing healthcare demand, expansion of pharmaceutical manufacturing, regulatory compliance, export opportunities, and product portfolio development.
What should investors evaluate before investing?
Investors should evaluate the company’s financial performance, manufacturing capabilities, regulatory compliance, valuation, competitive position, industry outlook, and associated risks before making an investment decision.
Conclusion
The Sai Parenterals IPO provided investors with an opportunity to participate in a pharmaceutical manufacturing company serving domestic and international healthcare markets. Through its manufacturing capabilities, diversified product portfolio, quality-focused operations, and regulatory compliance, the company has established a business model aimed at long-term growth.
As demand for pharmaceutical products and healthcare services continues to expand, the company may benefit from favourable industry trends. However, sustained growth will depend on efficient manufacturing, product quality, regulatory compliance, prudent financial management, and successful execution of its expansion strategy.
Before making an investment decision, investors should carefully analyse the company’s financial performance, valuation, competitive position, long-term business strategy, and associated risks to determine whether the Sai Parenterals IPO is suitable for their investment objectives.
